Avanos Medical, Inc. (AVNS) Stock
AVNS Key Statistics
About Avanos Medical, Inc.
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
CEO: David C. Pacitti. Company website
AVNS — Frequently Asked Questions
What is the AVNS stock price today?
Avanos Medical, Inc. (AVNS) trades at $24.63, up 69.51% on the day, as of Sep 20, 2026 15:00 UTC.
What is Avanos Medical, Inc.'s market cap?
Avanos Medical, Inc. has a market capitalisation of $1.15B, calculated from the live AVNS share price and shares outstanding.
What is the P/E ratio of AVNS?
AVNS has no meaningful price-to-earnings ratio: Avanos Medical, Inc. lost $1.47 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Avanos Medical, Inc. make?
Avanos Medical, Inc. generated revenue of $701.20M over the trailing twelve months, which puts the stock at 1.63 times sales.
What is the 52-week range for AVNS?
AVNS has traded between $12.75 and $24.70 over the past 52 weeks, and the last price is 0.3% below that high.
Is Avanos Medical, Inc. profitable?
No. Avanos Medical, Inc. is loss-making, with a net margin of -9.68% over the trailing twelve months.
What is the analyst price target for AVNS?
Wall Street analysts rate AVNS Hold, with an average price target of $23.00, 6.6% below the current price.
What sector is Avanos Medical, Inc. in?
Avanos Medical, Inc. is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US .
Who is the CEO of Avanos Medical, Inc.?
David C. Pacitti is the chief executive of Avanos Medical, Inc., which employs 2,227 people.
Where can I track AVNS in real time?
QFI Terminal shows AVNS with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See AVNS live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open AVNS in Terminal See plans